On October 11th, a good news came from Tianjin Tianyao Pharmaceuticals Co.,Ltd., the Notice of Approval for the Launching Application of Chemical APIs for glycylglutamine and glycyltyrosine was approved and issued by National Medical Products Administration. This means that Tianjin Tianyao Pharmaceuticals Co.,Ltd. has two new API products that can be sold in China, and the domestic market space of the company will be further expanded.

It is reported that glycylglutamine and glycyltyrosine are both dipeptide amino acids, and compound amino acid (15) and dipeptide (2) injection are one of the main components. The compound preparation of glycyl-glutamine is mainly used for treating critically ill patients with trauma, septicemia and some organ failure. The compound preparation of glycyltyrosine is suitable for treating patients who can't be supplemented by oral or intestinal nutrition, and those who can't meet the needs by supplementing nutrition through these ways, especially for patients with moderate to severe catabolism.

In recent years, Tianjin Tianyao Pharmaceuticals Co.,Ltd. has made many positive achievements in new drug registration, qualification certification and consistency evaluation at home and abroad. Up to now, in China, more than ten products of Tianjin Tianyao Pharmaceuticals Co.,Ltd. have passed the consistency evaluation one after another, and many products have been granted the Drug Registration Certificate. Many steroid hormone APIs such as prednisone, spironolactone, dexamethasone, methylprednisolone of Tianjin Tianyao Pharmaceuticals Co.,Ltd. have passed the FDA certification in the United States, the company obtained CEP certificates for more than ten products. The approval of glycylglutamine and glycyltyrosine for launching will further enrich the company's product structure and boost company's business development.